glp-1 obesity drugs news today 2025 Pharmacy Pricing Update (Dec 2025) GLP-1 Trends: Access & Shortages,

Increasing data are showing that weight loss with these medications has increased fertility

In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig

Therefore, long-acting GLP-1 receptor agonists offer a viable treatment option for people with type 2 diabetes and effectively align with the ADAs standard of care recommendations by addressing more than just blood glucose levels

Considerations for the pharmacological treatment of diabetes in older adults

Researchers are still exploring the link between protein and GLP-1 production, and more human studies are ultimately needed